Verdict: Side-by-side breakdown using the Bull Rankings model. REGN scored 68.1, ADMA scored 86.3 — ADMA leads.
Compare another set
REGN
Regeneron Pharmaceuticals, Inc.
Biotechnology · Quality-Growth
68.1
$746.54 · $76.9B
fundamentals as of
Score gap
18.2
ADMA leads
ADMA
ADMA Biologics, Inc.
Biotechnology · Quality-Growth
86.3
$10.36 · $2.3B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
CheapestADMA14.8x
Fastest growthADMA+19.6%
Strongest balance sheetREGN0.09
Highest qualityADMA87 / 100
Largest discount to fair valueADMA-28%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
REGN
stronger →← stronger
ADMA
65
Qualityreturns · margins · balance sheet
87
76
Growthrevenue & earnings expansion
91
64
Valuevaluation vs sector peers
81
ADMA is stronger on 3 of 3 pillars.
Fundamentals, head-to-head
REGN
ADMA
$3.8bB
FCF
$116mC
+9.3%B
Rev
+19.6%B+
0.09B+
D/E
0.50B
18.5xA-
P/E
14.8xA-
1.26B
PEG
0.80A-
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
REGN
ADMA
22% above
Price vs fair valuelower is cheaper
28% below
~12%/yr
Growth the price impliesyr-1 FCF growth, fading to 4% · lower = less priced in
~4%/yr
-24%
1-yr DCF upside
+13%
-18%
5-yr DCF upside
+38%
-9%
10-yr DCF upside
+88%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
REGN
Why this score
Diluting shareholders
ADMA
Why this score
Buying back stock
Durable high returns
Earnings outpace cash
The companies
REGNRegeneron Pharmaceuticals, Inc.
Biotechnology · $746.54 · beta 0.15
Why now
Biotechnology · market cap $76.9b. 13% off the 52-week high of $859.34. 26 sell-side analysts rate this a Buy with a mean 1-yr target of $859.04 (implying +15% upside).
Moat
Net margin 28% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 14% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. $76.9b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
ADMAADMA Biologics, Inc.
Biotechnology · $10.36 · beta 0.69
Why now
Biotechnology · market cap $2.3b. Down 49% from 52-week high of $20.46 — deep drawdown territory. Revenue growing +20%, comfortably above the S&P median. PEG 0.80 — paying under fair value for the growth rate. 4 sell-side analysts publish a mean 1-yr target of $17.00 (implying +64% upside).
Moat
Net margin 33% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 42% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Down 49% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where REGN and ADMA diverge
On the headline score the gap is 18.2 points in favor of ADMA. The widest single difference is Quality, where ADMA leads by 22.1 points.
QualityREGN 65.0 · ADMA 87.1ADMA +22.1
ValueREGN 63.9 · ADMA 80.8ADMA +16.9
GrowthREGN 76.1 · ADMA 91.4ADMA +15.3
Pillars run 0–100. Value is judged against each company's own sector, so a Value score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.
Common questions
Is ADMA or REGN the better stock?
ADMA scores higher: ADMA 86.3, REGN 68.1 out of 100 on the Bull Rankings quality-growth score, which blends business quality, growth and valuation into one number. A higher score means a stronger business at a more reasonable price — it is not a price target or a recommendation.
Where do ADMA and REGN differ most?
The widest gap is quality, where ADMA leads by 22 points on the 0–100 pillar scale. ADMA leads all three pillars, so the gap is broad rather than a single-measure difference.
How are ADMA and REGN scored?
Each carries the same 0–100 quality-growth score used everywhere on the site, built from three pillars — quality (profitability and returns on capital), growth (revenue and earnings), and value (what you pay for them) — combined as a geometric mean, so a weak pillar cannot be papered over by a strong one.
How current is this comparison?
The whole universe is re-scored every trading day after the US market close, so the scores and fundamentals here reflect the latest published edition.